BridgeMD
New treatment option for Advanced Prostate Cancer
Official title Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
ClinicalTrials.gov ID: NCT06335914
What this study is testing
- What it's testing
- This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Male, age ≥ 18 years
- Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
- Poor risk patients with mCSPC at study enrollment
- De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
- High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
You likely can't join if
- Under a assigned by chance-controlled trial with unknown allocation of systemic therapy
- Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
- Unable to provide written consent by patient and their legal representatives
- In the opinion of the treating physician:
- conditions which would significantly impair the patient's ability to comply with study procedures and follow up
- Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
See the full eligibility criteria
- Male, age ≥ 18 years
- Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
- Poor risk patients with mCSPC at study enrollment
- De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
- High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
- Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
- No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
- Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility
- Under a assigned by chance-controlled trial with unknown allocation of systemic therapy
- Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
- Unable to provide written consent by patient and their legal representatives
- In the opinion of the treating physician:
- conditions which would significantly impair the patient's ability to comply with study procedures and follow up
- Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
- another active malignancy
- patient on dialysis
- another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.